Effects of Single Nucleotide Polymorphisms in c-Myc on Stable Warfarin Doses in Patients With Cardiac Valve Replacements

References

• Ansell J , HirshJ , HylekE , JacobsonA , CrowtherM , PalaretiG . Pharmacology and management of the vitamin k antagonists . Chest133 ( 6 ), 160S – 198S ( 2008 ).
   PubMed Web of Science ®Google Scholar
• D’andrea G , D’ambrosioRL , Di PernaPet al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose–anticoagulant effect of warfarin . Blood105 ( 2 ), 645 – 649 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Sandanaraj E , LalS , CheungYBet al. VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients . Drug Metab. Pharmacokinet.24 ( 4 ), 365 – 375 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Zhao F , LokeC , RankinSCet al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose . Clin. Pharmacol. Ther.76 ( 3 ), 210 – 219 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Moridani M , FuL , SelbyRet al. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort . Clin. Biochem.39 ( 6 ), 606 – 612 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Caldwell MD , AwadT , JohnsonJAet al. CYP4F2 genetic variant alters required warfarin dose . Blood111 ( 8 ), 4106 – 4112 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Borgiani P , CiccacciC , ForteVet al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population . Pharmacogenomics10 ( 2 ), 261 – 266 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Lasker JM , ChenWB , WolfI , BloswickBP , WilsonPD , PowellPK . Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11 . J. Biol. Chem.275 ( 6 ), 4118 – 4126 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Gebremdhin D , YamauraK , HarderDR . Role of 20-HETE in the hypoxia-induced activation of Ca2+-activated K+ channel currents in rat cerebral arterial muscle cells (vol 294, pg h107, 2007) . Am. J. Physiol. Heart Circ. Physiol.294 ( 2 ), H1101 – H1101 ( 2008 ).
   Web of Science ®Google Scholar
• Renic M , KlausJA , OmuraTet al. Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion . J. Cereb. Blood Flow Metab.29 ( 3 ), 629 – 639 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Rieder MJ , ReinerAP , GageBFet al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose . N. Engl. J. Med.352 ( 22 ), 2285 – 2293 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Chen YH , XuJH , BorowiczS , CollinsC , HuoDZ , OlopadeOI . c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells . BMC Cancer11 , 13 ( 2011 ).
   Web of Science ®Google Scholar
• Wirtenberger M , HemminkiK , ForstiAet al. c-MYC Asn11Ser is associated with increased risk for familial breast cancer . Int. J. Cancer117 ( 4 ), 638 – 642 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Cole MD . MYC association with cancer risk and a new model of MYC-mediated repression . Cold Spring Harb. Perspect. Med.4 ( 7 ), 13 ( 2014 ).
   Web of Science ®Google Scholar
• Pfister A , OsmanA . The VKORC1 promoter is occupied by c-Myc transcription factor in HepG2 cells . Thromb. Res.126 ( 2 ), E150 – E151 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Sotelo J , EspositoD , DuhagonMAet al. Long-range enhancers on 8q24 regulate c-Myc . Proc. Natl Acad. Sci. USA107 ( 7 ), 3001 – 3005 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Gabriel SB , SchaffnerSF , NguyenHet al. The structure of haplotype blocks in the human genome . Science296 ( 5576 ), 2225 – 2229 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Sotelo J , EspositoD , DuhagonMAet al. Long-range enhancers on 8q24 regulate c-Myc . Proc. Natl Acad. Sci. USA107 ( 7 ), 3001 – 3005 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wadelius M , ChenLY , LindhJD . The largest prospective warfarin-treated cohort supports genetic forecasting (vol 113, pg 784, 2009) . Blood123 ( 7 ), 1113 – 1113 ( 2014 ).
   Web of Science ®Google Scholar
• Whitlock RP , SunJC , FremesSE , RubensFD , TeohKH . Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines . Chest141 ( 2 Suppl. ), e576S – S600 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Sun XA , HuSS , QiGQ , ZhouYY . Low standard oral anticoagulation therapy for Chinese patients with St. Jude mechanical heart valves . Chin. Med. J. (Engl.)116 ( 8 ), 1175 – 1178 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Matsuyama K , MatsumotoM , SugitaTet al. Anticoagulant therapy in Japanese patients with mechanical mitral valves . Circ. J.66 ( 7 ), 668 – 670 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Yoon IK , LeeKE , LeeJK , ChangBC , GwakHS . Adequate intensity of warfarin therapy for Korean patients with mechanical cardiac valves . J. Heart Valve Dis.22 ( 1 ), 102 – 109 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gearhart J , PashosEE , PrasadMK . Pluripotency redux – advances in stem-cell research . N. Engl. J. Med.357 ( 15 ), 1469 – 1472 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Massari ME , MurreC . Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms . Mol. Cell. Biol.20 ( 2 ), 429 – 440 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Owen RP , GongL , SagreiyaH , KleinTE , AltmanRB . VKORC1 pharmacogenomics summary . Pharmacogenet. Genomics20 ( 10 ), 642 – 644 ( 2010 ).
   PubMed Web of Science ®Google Scholar